Crizotinib for c-MET-amplified advanced NSCLC: a single-center experience

Tacar S. Y., Yilmaz M., ÖZ A. B., Tural D.

TUMORI JOURNAL, vol.108, no.3, pp.258-262, 2022 (SCI-Expanded, Scopus) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 108 Issue: 3
  • Publication Date: 2022
  • Doi Number: 10.1177/03008916211009303
  • Journal Name: TUMORI JOURNAL
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus, BIOSIS, EMBASE, MEDLINE
  • Page Numbers: pp.258-262
  • Keywords: MET amplification, lung cancer, crizotinib, CELL LUNG-CANCER, TYROSINE KINASE, CHEMOTHERAPY, RESISTANCE, INHIBITORS, MUTATIONS, GEFITINIB, OCCURS
  • Istanbul University-Cerrahpasa Affiliated: No

Abstract

Introduction: Lung cancer is the most common cause of cancer-related death in the world. Changes in the treatment of metastatic lung cancer in recent years have made targetable mutations gain importance. MET alteration is one of these driver mutations and crizotinib is a tyrosine kinase inhibitor used in therapy.